Table D8. Participant baseline characteristics

| Author, Year  Trial Name | Baseline Age - Mean (SD) | Baseline % Female | Race/Ethnicity % | Other Baseline Characteristics Reported | Specify Characteristic and Group Differences | Add Comments or Specify "Other" Entries |
| --- | --- | --- | --- | --- | --- | --- |
| Bender et al., 20101 NA | Overall N: NR G1: 39.6 (12.8) G2: 43.5 (14.3) | Overall N: NR G1: 60% G2: 68% | **White** G1: 56% G2: 60%  **Hispanic** G1: 24% G2: 12% **African American** G1: 20% G2: 20% **Asian** G1: 0% G2: 8% | No | NA | **Other (Theory)**: Benefit-risk model of health behavior. |
| Berg et al., 19972 NA | Overall N: 55 G1: 47 (15) G2: 52 (15) | Overall N: 55 G1: 21 (68%) G2: 15 (62%) | Overall N: 55 **Caucasian** G1: 29 (93%) G2: 23 (96%)  **non-Caucasian** G1: 2 (7%) G2: 1 (4%) | Yes | **Income** Overall N: 55 <10K G1: 20% G2: 12% 10-30K G1: 43%  G2: 29% 30-50% G1: 17% G2: 25%  **Insurance (yes)** G1: 93% G2: 87%  **Health problems** G1: 48% G2: 54% |  |
| Berg et al., 19972 NA  (continued) |  |  |  |  | **Asthma severity moderate** G1: 71% G2: 79% severe G1: 29%  G2: 21%  **Health Problems** (yes) G1: 48% G2: 54%  **Chronolog compliance mean** (SD) G1: 43 (29) G2: 40 (26)  No sig diff |  |
| Berger et al., 20053  NA | Overall N: 367  Overall age: 45.98 (9.13)  G1: NR  G2: NR | Overall N: 367  Overall % female: 82.8  G1: NR  G2: NR | Overall N: NR  G1: NR  G2: NR | No | NR |  |
| Bogner et al., 20084 NA | Overall N: 64 G1: 59.7 (7.3) G2: 57.5 (6.3) | Overall N:  G1: 24 (75.0) G2: 25 (78.1) | African American, n (%) G1: 25 (78.1)  G2: 28 (87.5) | Yes | **SF-36 scores:** **Physical function score, mean (SD)**  G1: 54.1 (33.2) G2: 64.5 (34.9) p= .22  **Social function score, mean (SD)**  G1: 75.6 (37.6)  G2: 83.8 (33.5)  p=.37 | **Funding** multiple sources: American Heart Association Grant-in-Aid, and an NIMH Mentored Patient-Oriented Research Career Development Award  **Theory**: Integrated Care Model |
| Bogner et al., 20084 NA  (continued) |  |  |  |  | **Role physical score, mean (SD)** G1: 55.5 (42.0) G2: 65.6 (42.5)  p= .34  **Role emotional score, mean (SD)** G1: 63.5 (46.7) G2: 74.0 (43.0) p= .36  **Bodily pain score, mean (SD)** G1: 46.3 (33.1) G2: 60.6 (35.7)  p= .10  **Other covariates** **MMSE, mean (SD)** G1: 27.7 (2.7) G2: 27.9 (3.2)  p= .73  **Number of medications, N (SD)** G1: 8.6 (5.1) G2: 7.0 (3.6)  p= .16  **Outcome measures** **CES-D, mean (SD)**  G1: 17.5 (13.2) G2: 19.6 (14.2) p=.54 |  |
| Bogner et al., 20084 NA  (continued) |  |  |  |  | **Systolic BP, mean (SD), mm Hg**  G1: 146.7 (20.9) G2: 143.1 (22.5)  p= .51  **Diastolic BP, mean (SD), mm Hg** G1: 83.0 (10.7)  G2: 81.4 (11.1) p=.58  ≥**80% adherent to antidepressant, N (%)**  G1: 14 (43.0) G2: 16 (50.0)  p= .81  **≥80% adherent to antihypertensive, N (%)** G1: 16 (50.0) G2: 11 (34.4)  p= .31 |  |
| Bogner et al., 20105  NA | Overall N: Mean (SD) = 60.2 (7.4)  G1: 61.6 (8.3)  G2: 58.3 (6.3) | Overall N: 84.5%  G1: 82.8%  G2: 86.2% | **Black**  Overall N: 100%  G1: 100%  G2: 100% | Yes | **Less than high school education**  Overall N: 13  G1: 8 (27.6%)  G2: 5 (17.2%)  **Lives alone**  Overall N: 27  G1: 16 (55.2%)  G2: 11 (37.9%)  **Role Physical Score**  Overall N: NR  G1: 44.0 (39.9)  G2: 64.5 (42.5)  **Number of Medications**  Overall N: NR  G1: 10.2 (3.3)  G2: 7.7 (3.2)  **Adherent at baseline oral hypoglycemics** Overall N: NR  G1: 34.5%  G2: 20.7%  **Adherent at baseline anti-depressants**  Overall N: NR  G1: 27.6%  G2: 13.8% | **Funding source**  Non-profit (American Diabetes Association) and Academic (University of Pennsylvania's Institute on Aging)  **Theoretical model** Conceptual framework adapted from Cooper et al (source 33) |
| Bosworth et al., 20056 V-STITCH | Overall N: NR G1: 63 (11.24) G2: 64 (11.48) | Overall N: NR G1: 2% G2: 2% | **White** Overall N: NR G1: 56 G2: 58  **African-American** Overall N: NR G1: 41 G2: 39 | Yes | **High school or less, %** Overall N: NR G1: 50 G2: 51  **Inadequate income, %** Overall N: NR G1: 23 G2: 21  **Diabetic, %** Overall N: NR G1: 38 G2: 42  **Adherent to medications (based on self-report), %** Overall N: 66 G1: NR G2: NR | **Additional theoretical model**: Health Decision **Theoretical Model** HDM |
| Bosworth et al., 20087 TCYB  Bosworth et al., 20078 TCYB Methods paper | Overall N: NR G1: 61 (12.7) G2: 62 (11.9) | Overall N: NR G1: 65 G2: 67 | **Caucasian, %** Overall N: NR G1: 50% G2: 47% **African American, %** Overall N: NR G1: 47% G2: 51% | Yes | **12th grade or less**  Overall N: NR G1: 35% G2: 38%  **Functionally illiterate (REALM<=60), %** Overall N: NR G1: 27% G2: 27%  **Inadequate income, %** Overall N: NR G1: 18% G2: 21%  **Diabetic, %** Overall N: NR G1: 34% G2: 38% | **Funding source:** NHLBI, Pfizer Health Literacy Communication Initiative grant, American Heart Association Established-Investigator award **Theoretical model:** also Health Decision Model and motivational interviewing |
| Capoccia et al., 20049 NA | Overall N: 74 G1: 38.2 ± 13.8 G2: 39.4 ± 13.4 p=0.71 | Overall N: 57 (77) G1: 34 (83) G2: 23 (70) p=0.18 | **Non-White** Overall N: 16 (22) G1: 9 (22) G2: 7 (21) p=0.94 | Yes | **Annual household income <$30,000** Overall N: 19 (26) G1: 12 (29) G2: 7 (21) p=0.36  **Panic disorder** G1: 9 (22) G2: 5 (15) p= 0.43  **Neuroticism score** (Mean ± S.D. NEO) G1: 12.4 ± 6.1 G2: 11.0 ± 5.5 p= 0.31  **Dysthymic disorder** G1: 23 (56) G2: 16 (48) p= 0.40  **Prior antidepressant for depression** G1: 20 (49) G2: 12 (36) p= 0.28  **Prior counseling or psychotherapy** G1: 17 (41) G2: 17 (52) p= 0.39 |  |
| Capoccia et al., 20049 NA  (continued) |  |  |  |  | **Mean ± S.D. SCL-20 score** **No. (%) with SCID major depression** G1: 21 (53) G2: 9 (28) p= 0.04  **Mean ± S.D. SF-12 Index (physical) score** G1: 49.6 ± 1.6 G2: 52.6 ± 1.6 p= 0.68  **Mean ± S.D. SF-12 Index (mental) score** G1: 28.0 ± 1.6 G2: 29.0 ± 1.7 p= 0.20 |  |
| Carter et al., 200910 NA | Overall N: NR G1: 57.3 (14.3) G2: 59.2 (13.8) | Overall N: NR G1: 62.5% G2: 55.7% | **White/Caucasian** Overall N: NR G1: 85.9% G2: 77.6% **African-American** Overall N: NR G1: 6.8% G2: 19.5% **American Indian** Overall N: NR G1: 0.5% G2: 1.0% **>1 Race or Other** Overall N: NR G1: 2.6% G2: 1.9% | Yes | **Low self-reported medication** **adherence (i.e., score >3) (%)** Overall N: NR G1: 8.9% G2: 9.1% NS  **Household income <$25,000 (%)** Overall N: NR G1: 21.4% G2: 51.9% p < 0.001 |  |
| Carter et al., 200910 NA  (continued |  |  |  |  | **Insurance status (%):** Individual/group plan  G1: 56.3% G2: 32.4% Medicare/Medicaid G1: 37.0% G2: 40.5% Self-pay or other G1: 6.8% G2: 27.1% p < 0.001  **Married** Overall N: NR G1: 67.7%% G2: 43.3% p: <0.001  **BMI (kg/m^2) (Mean (SD))** Overall N: NR G1: 32.1 (6.8) G2: 34.2 (8.7) p: 0.010  **Diabetes mellitus (%)** Overall N: NR G1: 19.8% G2: 38.1% p < 0.001  **Heart failure (%)** Overall N: NR G1: 0.5% G2: 1.9% NS |  |
| Carter et al., 200910 NA  (continued |  |  |  |  | **Chronic kidney** **disease (%)** Overall N: NR G1: 5.7% G2: 7.6% NS  **Angina (%)** Overall N: NR G1: 0.5% G2: 5.7% p < 0.003  **Peripheral arterial disease (%)** Overall N: NR G1: 2.1% G2: 1.9% NS **Left ventricular hypertrophy (%)** Overall N: NR G1: 1.6% G2: 1.4% NS  **>1 Coexisting condition (%)** Overall N: NR G1: 90.1% G2: 95.2% p=0.051  **No. of coexisting conditions (Mean (SD))** Overall N: NR G1: 2.8 (1.8) G2: 3.6 (2.2) p < 0.001 |  |
| Chernew et al., 200811 NA | Overall N (2004):  G1: 37.4 G2: 43.9  Overall N (2005): G1: 38.0 G2: 44.7 | Overall N (2004):  G1: 53.5 G2: 51.2  Overall N (2005): G1: 53.5 G2: 51.2 | NR | No | NA | "**Other" Theoretical Model** = None specified **"Other" Level of Randomization** = Not applicable |
| Choudhry et al., 201012  NA | Total sample Overall N: NR  G1: 58.8 (NR)  G2: 67.5 (NR)  G3: 53.8 (NR)  G4: 54.5 (NR)  G1 and G3: p<0.05  G2 and G4 p<0.05 | Total sample Overall N: NR  G1:36.1%  G2: 37.6%  G3: 39.8%  G4: 28.8%  G1 and G3: p<0.05  G2 and G4 p<0.05 | **Black**  Total sample  Overall N: NR  G1: 11.5%  G2:10.2%  G3: 11.9%  G4: *12.3%*  *G2 and G4 p<0.05* | Yes | **Income (Mean):**  Overall: NR  G1: $56,625  G2: $54,715  G3: $58,263  G4: $57,286  **Coronary artery disease (%):**  Overall N: NR  G1: 26.3%  G2: 60.6%  G3: 25.3%  G4:43.8%  **Congestive heart failure:**  Total sample: Data NR  **Statin users**  Overall N: NR  G1: 1.8%  G2: 1.8%  G3: 1.8%  G4: 2.4%  **Hypertension:**  Overall: NR  G1: 50.0%  G2: 55.5%  G3: 59.5%  G4: 46.4% | Study design - Other = Interrupted time series with concurrent control group  Level of randomization - Other = NA  Theoretical model - Other = Value-based insurance design strategy |
| Choudhry et al., 201012  NA  (continued) |  |  |  |  | **Diabetes**:  Overall: NR  G1: 36.2%  G2: 12.6%  G3 34.5%  G4: 9.9%  **Charlson comorbidity score:**  Overall: NR  G1: 1.0  G2: 3.3  G3: 1.0  G4: 3.3  **Monthly drug copay (year before copay reduction):**  Overall: NR  G1: $24.18  G2: $17.22  G3: $11.80  G4: 10.65  G1 and G3 differ on income, hypertension and copay at p < 0.05  G2 and G4 differ income, CAD, Hypertension, diabetes and copay at p < 0.05 |  |
| Choudhry et al., 201113 | Overall N: 5855 G1: 53.6 (7.6) G2: 53.7 (7.6) | Overall N: 5855 G1: 24.4 G2: 25.3 | Overall N: NR G1: NR G2: NR | Yes | **Congestive heart failure**  Overall N: 5855  G1: 27.0  G2: 29.1  **COPD**  Overall N: 5855  G1: 15.7  G2: 16.4  **Diabetes**  Overall N: 5855  G1: 34.3  G2: 34.8  **Hypertension**  Overall N: 5855  G1: 71.2  G2: 72.4  **Previous MI**  Overall N: 5855  G1: 15.6  G2: 17.4  **Stroke**  Overall N: 5855  G1: 5.8  G2: 6.7 | NA |
| Friedman et al., 199614  NA | Overall N: 76  G1: 76  G2: 77 | Overall N: 77  G1: 75  G2: 79 | **Black %**  Overall N: 11%  G1: 10%  G2: 11% | Yes | **Education (%):**Overall N: NR  1-11  G1: 20  G2: 32  12  G1: 55  G2: 51 | **"Other" theoretical model** = none specified |
| Friedman et al., 199614  NA  (continued) |  |  |  |  | 13-17  G1: 25  G2: 17  **Employed (%)**  G1: 9  G2: 10  **Comorbid disease** (%)  Heart disease  G1: 29  G2: 34  Stroke  G1: 6  G2: 7  Diabetes  G1: 20  G2: 16  Other  G1: 80  G2: 82  **Mean number of comorbid disease**  G1: 1.2  G2: 1.2  **Mean medication adherence**  G1: 93  G2: 94  **Mean systolic BP (mm Hg)**  G1: 169.5  G2: 167 |  |
| Friedman et al., 199614  NA  (continued) |  |  |  |  | **Mean diastolic BP (mm Hg)**  G1: 86.1  G2: 84.0 |  |
| Fulmer et al., 199915  NA | Overall N: 50  G1: 73.1 (6.5)  G2: 76.2 (8.8)  G3: 73.7 (5.3) | Overall N: NR  G1:  G2: | Overall N: 50  **White**  G1: 23.5  G2: 20.0  G3: 0.0  **Black**  G1: 23.5  G2: 33.3  G3: 33.3  **Other**  G1: 50.0  G2: 46.7  G3: 61.1 | yes | **Average compliance rates at BL**  G1: 82%  G2: 76%  G3: 81% | **Funding Source:** Pharma, private foundation  **Theoretical Model:** Article describes using a "stimulant strategy" |
| Grant et al., 200316 NA | Overall N: (for all randomized to G1 and G2) NR G1: 63.3 (12.7) G2: 64.9 (12.1) Overall N: for completers (NR) G1: 64 (12) G2: 69 (10) | Overall (all randomized to G1 and G2) N: NR G1: 52 G2: 51 Overall N (all completers): NR G1: 55 G2: 69 | Overall N randomized: NR  G1: % white: 79  G2: % white: 89 Overall N for completers: NR G1: % white: 87  G2: % white: 93 | Yes | **Baseline Medication Adherence (# days adherent in last 7 days)** Overall N for completers: NR G1: 6.7 (0.9)  G2: 6.9 (0.4)  **HbA1c (mean (SD))** Overall (all randomized to G1 or G2: NR G1: 7.7 (1.6) G2: 7.6 (1.4) Overall N (completers): NR G1: 7.7 (1.7) G2: 7.5 (1.1)  **Number of Medicines (mean (SD))** Overall N (Completers): NR G1: 6 (2.8) G2: 5.8 (2.7) | **Other Theoretical Model** = None |
| Guthrie et al., 200117  First Myocardial Infarction (MI) Risk Reduction Program | Overall N: 58.0 (NR)  G1: 57.9 (NR)  G2: 58.3 (NR) | Overall N: 51.1  G1: 50.8  G2: 52.4 | **White**  Overall N: 79.9  G1: 80.0  G2: 79.6  **Black**  Overall N: 9.0  G1: 9.0  G2: 9.2  **Hispanic**  Overall N: 6.4  G1: 6.4  G2: 6.4  **Asian**  Overall N: 1.8  G1: 1.7  G2: 2.2 | Yes | **Prescription health plan, %**  Overall N: 77.4  G1: 77.5  G2: 77.2  **Level of education-elementary, %**  Overall N: 9.8  G1: 9.8  G2: 9.4  **Level of education-high school, %**  Overall N: 53.8  G1: 53.9  G2: 53.4  **Level of education-college, %**  Overall N: 25.9  G1: 25.8  G2: 26.2  **Level of education-graduate or professional, %**  Overall N: 10.6  G1: 10.5  G2: 10.9 | **Theoretical model**: not specified  **<$15,000, %**  Overall N: 20.6  G1: 21.0  G2: 19.0  **$15,001-$25,000, %**  Overall N: 21.2  G1: 21.2  G2: 21.4  **$25,001-$50,000, %**  Overall N: 31.0  G1: 31.1  G2: 30.8  **$50,001-$100,000, %**  Overall N: 21.7  G1: 21.1  G2: 23.7  **>$100,000, %**  Overall N: 5.5  G1: 5.6  G2: 5.1  **Diabetic (male), %**  Overall N: 8.8  G1: 8.1  G2: 8.9  **Diabetic (female), %**  Overall N:9.8  G1: 9.6  G2: 9.8 |
| Hoffman et al., 200318 NA | Overall N: NR G1: 51.9 (16.7) G2: 51.2 (16.5) | Overall N: 68 G1: 67.9 G2: 67.6 | NR | No | NA | **Other (Level of randomization):** random selection of zip codes of physicians' offices for inclusion in study. Allocation conducted by listing zip codes numerically and alternating arms.  **Multiple funding sources:** Pharma companies & insurance provider  **Theoretical Model:** No theoretical model reported |
| Hunt et al., 200819  NA | Overall N: NR G1: 68 (12) G2: 68 (13) | Overall N: NR G1: 63 G2: 66 | NR | Yes | **Comorbidities, N (%):** Overall N: NR **G1:**  Asthma or COPD, 27 (12) Diabetes, 59 (26) History of stroke, 15 (7) Coronary artery disease, 46 (20) Renal impairment, 8 (3) One or more chronic conditions, 111 (48) Baseline systolic BP (mean (SD)), 173 (15) Baseline diastolic BP (mean (SD)), 90 (14) |  |
| Hunt et al., 200819  NA  (continued) |  |  |  |  | **G2**:  Asthma or COPD, 27 (12) Diabetes, 57 (25) History of stroke, 6 (3) Coronary artery disease, 43 (18) Renal impairment, 6 (3) One or more chronic conditions, 103 (44) Baseline systolic BP (mean (SD)), 174 (15) Baseline diastolic BP (mean (SD)), 92 (14)  **Education, college, N (%)** G1: 64 (28) G2: 65 (28)   Only statistical sig between group difference was history of stroke, p=0.04 |  |
| Janson et al., 200320  NA | Overall N: 65  G1: 32 (9)  G2: 35 (8) | Overall N: G1: 18 (55%)  G2: 18 (56%) | NR | Yes | No group differences at baseline:  **BL values: Adherence to inhaled corticosteroid (%)**  G1: 70 (30)  G2: 65 (34) | col X: no explicit theory used but testing whether imparting basic information and skills will lead to behavior that will improve asthma control |
| Janson et al., 200320  NA  (continued) |  |  |  |  | **Quality of life\***  G1:27 (13)  G2: 24 (14)  **Perceived control of asthma**  G1: 37 (6)  G2: 42 (5)  **Symptom severity**  G1:11 (6)  G2: 7 (6)  **Beta-agonist (puffs)**  G1: 4 (3)  G2: 3 (3)  **FEV1 (% predicted)**  G1: 83 (17)  G2: 80 (20)  **Morning peak ﬂow (L/min)**  G1: 446 (125) G2: 363 (97)  **Eosinophil cationic protein**  G1: 319 +/- 277 G2: 324 (346)  **Tryptase ( g/L)**  G1: 10 (22)  G2: 3 (5)  **Eosinophil’s (%)**  G1: 6 (8)  G2: 7 (12) |  |
| Janson et al., 200320  NA  (continued) |  |  |  |  | **Neutrophils (%)**  G1: 39 (17)  G2: 44 (19) |  |
| Janson et al., 200921  NA | Overall N: 84  G1: 36.8 +/- 9.4  G2: 39.7 +/- 9.3 | Overall N: G1: 24 (53)  G2: 21 (54) | **Asian**  G1: 10 (22)  G2: 6 (15)  **Black**  G1: 1 (2)  G2: 4 (10)  **White**  G1: 28 (62)  G2: 26 (67)  **Other**  G1: 6 (14)  G2: 3 (8) | Yes | **Insured:**  Overall N: G1: 37 (82) G2: 27 (69)  **Severity by FEV1 criteria:** Severe (60% predicted value)  G1: 22 (49) G2: 18 (46);  **Adherence to ICS (%)**  G1: 82 +/- 18  G2: 81 +/- 18, p=.71  only statistically sign difference across groups: peak flow  **Peak ﬂow (morning only)**  G1: 427.4 +/- 91.1  G2: 381.8 +/- 110.2 , p=0.04  **Other markers of severity**: Perceived asthma control score (11-55)  G1: 41.8 +/- 6.1  G2: 40.2 +/- 4.2, p=.14 | **Funding sources** - gov't and pharma |
| Janson et al., 200921  NA  (continued) |  |  |  |  | **Asthma quality-of-life score (0-80)**  G1: 16.0 +/- 11.0 G2: 15.8 +/- 11.1, p=.94  **Peak ﬂow (morning only)**  G1: 427.4 +/- 91.1 G2: 381.8 +/- 110.2, p=.04  **Mean weekly puffs of b-agonist used**  G1: 1.5 +/- 1.9  G2: 1.7 +/- 2.2,  p= .71  **Mean weekly symptom score**  G1: 4.5 +/- 4.4  G2: 5.1 +/- 5.1, p=.55  **Mean % symptom-free days per week** G1: 34.1 +/- 37.1  G2: 31.0 +/- 37.2, p=.70  **Mean weekly number of nighttime awakenings**  G1: 0.29 +/- 0.69  G2: 0.35+/- 0.97, p=.75 |  |
| Johnson et al., 200622  NR | Overall N: NR  G1: NR  G2: NR | Overall N: 49.6  G1: NR  G2: NR | **White**  Overall N: 83.0  G1: NR  G2: NR  **Black**  Overall N: 5.8  G1: NR  G2: NR  **Other**  Overall N: 11.2  G1: NR  G2: NR | Yes | **Under $25,000, %**  Overall N: 21.8  G1: NR  G2: NR  **$25,000-$50,000, %**  Overall N: 33.1  G1: NR  G2: NR  **$50,000-$75,000, %**  Overall N: 21.8  G1: NR  G2: NR  **$75,000 or above, %**  Overall N: 23.4  G1: NR  G2: NR |  |
| Johnson et al., 200623  NR | Overall N: 55.7 (median) G1: NR  G2: NR | Overall N: 47.0  G1: NR  G2: NR | **White**  Overall N: 76.4  G1: NR  G2: NR  **Black**  Overall N: 16.1  G1: NR  G2: NR  **Other**  Overall N: 7.5  G1: NR  G2: NR | Yes | **Under $25,000, %**  Overall N: 15.9  G1: NR  G2: NR  **$25,000-$50,000, %**  Overall N: 29.1  G1: NR  G2: NR  **$50,000-$75,000, %**  Overall N: 22.1  G1: NR  G2: NR  **$75,000 or above,**  **%**  Overall N: 32.9  G1: NR  G2: NR | none |
| Katon et al., 199524 NA | Overall N: 217  Major depression group N=91 G1: 43.2 (15.4) G2: 42.3 (12.7)  Minor depression group N=126 G1: 52.2 (14.3) G2: 50.3 (15.1) | Overall N: 217  Major depression group N=91 G1: 77.5 G2: 88.1  Minor depression group N=126 G1: 76.3 G2: 68.7 | NR | yes | Overall N: 217  **SCL mean (SD) depression score** Major depression group N=91 G1: 2.35 (0.49) G2: 2.23 (0.48) Minor depression group N=126 G1: 1.67 (0.40) G2: 1.72 (0.56)  **IDS mean (SD) score** Major depression group N=91 G1: 46.6 (9.0) G2: 45.1 (11.2) Minor depression group N=126 G1: 29.1 (9.6) G2: 28.0 (9.5)  **Chronic disease score mean (SD) score** Major depression group N=91 G1: 1.3 (1.9) G2: 0.6 (1.4) Minor depression group N=126 G1: 2.3 (3.2) G2: 1.5 (1.9) | **Other Theoretical Model**: unspecified |
| Katon et al., 199625 NA | Overall N: NR Major Depression Group G1: 43.1 (9.3) G2: 44.8 (15.9)  Minor Depression Group G1: 49.2 (13.9) G2: 47.2 (13.8) | Overall N: NR Major Depression Group G1: 77.4 G2: 73.5  Minor Depression Group G1: 71.7 G2: 73.8 | Overall N: NR Major Depression Group (% White) G1: 77.4 G2: 91.2  Minor Depression Group (% White) G1: 91.3 G2: 85.7 | Yes | **>1 year of college (%)** Major Depression Group G1: 90.3 G2: 70.6  Minor Depression Group G1: 87.0 G2: 81.0  **Chronic disease (mean (SD)):** Overall N: NR Major Depression Group G1: 1.19 (1.6) G2: 1.1 (2.0)  Minor Depression Group G1: 1.5 (2.6) G2: 1.2 (2.3)  **Inventory of Depressive Symptoms Score (mean (SD))** Major Depression Group G1: 46.8 (10.8) G2: 46.0 (8.8)  Minor Depression Group G1: 27.3 (7.4) G2: 28.2 (11.3) | Column X: "Other" Theoretical Model = Social Cognitive theory and Social Learning theory |
| Katon et al., 199625 NA  (continued) |  |  |  |  | **SCL-20 (mean (SD))** Major Depression Group G1: 2.46 (0.53) G2: 2.35 (0.51)  Minor Depression Group G1: 1.77 (0.49) G2: 1.62 (0.54)  **Recurrent major depression (>2 episodes)** Major Depression Group G1: 59.1 G2: 65.4  Minor Depression Group G1: 66.7 G2: 64.9 |  |
| Katon et al., 200128  NA  Ludman et al., 200329 NA  Van Korff et al., 200330 NA | Overall N: 387 (reported as 386 in Ludman et al. and Katon et al.) G1: 46.4 (11.9) G2: 45.6 (13.3) | Overall N: 387 (reported as 386 in Ludman et al. and Katon et al.) G1: 75.4 G2: 71.9 | Overall N: 387 (reported as 386 in Ludman et al. and Katon et al.)  **% Caucasian**: G1: 92.3 G2: 88.0 | Yes | **Severity of Depression**  **% with major depression within past 2 years** Overall N: 387 (reported as 386 in Ludman et al. and Katon et al.) G1: 78.5 G2: 87.5 p=0.01  **SCL Depression Score (range 0 to 4), mean (SD)**  G1: 0.83 (0.39)  G2. 0.84 (0.35)  **Comorbidity: Chronic Disease Score, mean (SD)** G1: 1051.4 (1228.0) G2: 1009.2 (994.5) | NA |
| Katon et al., 199926  NA  Katon et al., 200227  NA | Overall N: NR  G1: 47.2 (14)  G2: 46.7 (13.4) | Overall N: NR  G1: 67.5  G2: 81.6  p= 0.02 | **% Caucasian**  Overall N: NR  G1: 79.8  G2: 80.7 | Yes | **Severity of Depression SCL Depression score**  G1: 1.9 (0.5)  G2: 1.9 (0.5)  **Moderate depression:** N=149  **Severe depression**: N=79  **Recurrent depression (>= 3 episodes), %**  G1: 76.3  G2: 83.3  **Dysthymia, %**  G1: 40.0  G2: 59.8  **Chronic disease score; mean (SD)**  G1: 1191.3 (978.5)  G2: 1368.3 (1292.9) | **Other Randomization**;: Patients stratified by severity of disease (moderate or high) prior to randomization.  **Other Theoretical Model**: NR |
| Lee et al., 200631 FAME | \*Overall N: 78 (8.3) G1: 77 (10.5) G2: 78 (6.2) | \*Overall N: 22.9 G1: 25.3 G2: 26.3 | **White** Overall N: 63.7 G1: 61.4 G2: 56.5  **Black** Overall N: 32.3 G1: 34.9 G2: 40.8 | Yes | **<High School, %** \*Overall N: 7.5 G1: 3.7 G2: 12.9  **High School graduate, %** \*Overall N: 33.8 G1: 32.1 G2: 38.6  **College graduate, %** \*Overall N: 21.4 G1: 24.7 G2: 18.6  **Drug-treated hypertension, %** \*Overall N: 91.5 G1: 92.8 G2: 90.8  **Drug-treated hyperlipidemia, %** \*Overall N: 80.6 G1: 83.1 G2: 80.3  **BL adherence at completion of run-in phase, mean (SD)** Overall N: 61.2 (13.5) G1: 61.4 (13.0) G2: 61.1 (14.1) | **Other Theoretical Model =** not specified  \*Overall N for baseline characteristics reported for beginning of run-in phase |
| Lin et al., 200632 NA | Overall N: Mean (SD) = 58.5 (NR) G1: Mean (SD) = 58.6 (11.8) G2: Mean (SD) = 58.1 (12.0) | Overall N: 66.6% G1: 65.2% G2: 64.8% | **White** Overall N: 80% G1: 81.1% G2: 75.2% No other race/ethnicity data provided | Yes | **Type 2 Diabetes** Overall N: NR G1: 96.3% G2: 95.8%  **Number of Diabetic Complications** G1: Mean (SD) = 1.5 (1.4) G2: Mean (SD) = 1.5 (1.3)  **Major Depression (co-morbidity)** Overall N: NR G1: 62.6%% G2: 69.1%  **>3 Previous Episodes of Depression (co-morbidity)** Overall N: NR G1: 68.6% G2: 60.5%  **BL SCL-20 Score (Depression severity)** Overall N: NR G1: Mean (SD) = 1.7 (0.5) G2: Mean (SD) = 1.6 (0.5) | **Other Theoretical model** = Intervention design and procedures based on the Pathways Study (source 24) |
| Maciejewski et al., 201033  NA | **Diuretics** Overall N: NR G1: 51.7 (7.9) G2: 52.0 (7.8)  **ACE Inhibitors** Overall N: NR G1: 51.8 (8.0) G2: 52.2 (7.9)  **Statins** Overall N: NR G1: 53.0 (7.3) G2: 53.4 (7.2)  **Beta Blockers** Overall N: NR G1: 52.0 (8.2) G2: 52.4 (8.0)  **Calcium Channel Blockers** Overall N: NR G1: 52.6 (7.8) G2: 52.8 (7.7)  **Metformin** Overall N: NR G1: 51.6 (8.4) G2: 51.7 (8.3)  **ARBS**  Overall N: NR G1: 52.3 (7.6) G2: 52.6 (7.5) | **Diuretics** Overall N: NR G1: 55% G2: 63%  **ACE Inhibitors** Overall N: NR G1: 38% G2: 45%  **Statins** Overall N: NR G1: 38% G2: 46%  **Beta Blockers** Overall N: NR G1: 46% G2: 54%  **Calcium Channel Blockers** Overall N: NR G1: 40% G2: 48%  **Metformin** Overall N: NR G1: 45% G2: 54% ARBS  Overall N: NR G1: 45% G2: 54% | Overall N: NR G1: NR G2: NR | Yes | Comorbidity burden (mean, SD) **Diuretics** Overall N: NR G1: 2.51 (2.59) G2: 2.51 (2.59)  **ACE Inhibitors** Overall N: NR G1: 2.82 (3.01) G2: 2.85 (3.02)  **Statins** Overall N: NR G1: 2.95 (3.03) G2: 2.95 (3.11)  **Beta Blockers** Overall N: NR G1: 3.51 (3.53) G2: 3.59 (3.72)  **Calcium Channel Blockers** Overall N: NR G1: 2.98 (3.24) G2: 3.09 (3.37)  **Metformin** Overall N: NR G1: 2.87 (2.54) G2: 2.88 (2.60)  **ARBS**  Overall N: NR G1: 2.90 (3.01) G2: 2.91 (3.11) | NA |
| Maciejewski et al., 201033  NA  (continued) | **Cholesterol Absorption Inhibitors** Overall N: NR G1: 53.5 (7.1)  G2: 53.8 (7.0) | **Cholesterol Absorption Inhibitors** Overall N: NR G1: 37% G2: 44% |  |  | **Cholesterol Absorption Inhibitors** Overall N: NR G1: 3.35 (3.19) G2: 3.40 (3.38) |  |
| Mann et al., 201034 The Statin Choice | Overall N: 58 (11.5) G1: 58 (12) G2: 58 (11) | Overall N: Text states 58%, but the numbers in the table are not consistent with that  G1: 74% G2: 75% | Overall N: Black or Latino: 89%  G1: Black or Latino: NR G2: Black or Latino: NR | Yes | **< HS Education** Overall N: 44% G1: 51% G2: 36%  **Mean HBA1c** Overall N: mean 7.5 (SD 2.0)  G1: 7.0 (6.4, 8.7) (median (IQR))  G2: 6.7 (6.3, 7.6) (mean (IQR))  **10 year Cardiovascular Risk (%)** Overall N:  < 15% risk: 53% 15-30% Risk: 44% > 30% Risk: 3% G1: < 15% risk: 53% 15-30% Risk: 40% > 30% Risk: 5% G2: < 15% risk: 54% 15-30% Risk: 41% > 30% Risk: 3%  **BL Statin Use** Overall N: 69%  G1: 69% G2: 69% |  |
| Motori et al., 201135 | Overall N: NR G1: median 67 (range 51-84) G2: median 67 (range 50-82) | Overall N: 100 G1: 100 G2: 100 | Overall N: NR G1: NR G2: NR | Yes | **Annual income** Overall N: NR G1: Median 50000 (range 25000-90000) G2: Median 35000 (range 25000-70000) | NA |
| Murray et al., 200736 NA | Overall N: NR G1: 61.4 (SD 7.7) G2: 62.6 (SD 8.8) | Overall N: NR G1: 68.0% G2: 66.1% | Overall N: NR G1: Black 45.1%, White 54.1%, Other 0.8% G2: Black 52.1%, White 46.9%, Other 1.0% | Yes | **Sufficient income** G1: 62% G2: 64%  **Mean education** G1: 11 (SD 2) G2: 11 (SD 3)  **Health literate** G1: 72% G2: 71%  **Medicare** G1: 54.1% G2: 56.3%  **Medicaid** G1: 30.3% G2: 36.5% |  |
| Nietert et al., 200937 NA | Overall N: 60 (16) G1: 59.9 (16.7) G2: 60.6 (16.0) G3: 59.7 (16.5) | Overall N: NR G1: NR G2: NR | **Black** Overall N: NR G1: 16.3% G2: 16.3% G3: 16.5% | Yes | **Income (Mean (SD))** Overall N: NR G1: $33,573 ($9029) G2: $33751 ($9339) G3: $33471 ($9448)  **Insurance Status** Medicaid G1: 16.4% G2: 13.2% G3: 15.7% Other G1: 72.8% G2: 76.2% G3: 73.1% None G1: 10.8% G2: 10.6% G3: 11.2%  **Disease indication Diabetes** G1: 12.2% G2: 12.2% G3: 10.5%  **Hypertension or heart failure** G1: 56.8% G2: 55.9% G3: 56.0%  **Hyperlipidemia** G1: 17.2% G2: 16.9%  G3: 17.7% | **Theoretical model - Other** = NS |
| Nietert et al., 200937 NA  (continued) |  |  |  |  | **Depression** G1: 13.2% G2: 14.6% G3: 15.1%  **Psychosis** G1: 1.4% G2: 1.2% G3: 1.2% |  |
| Okeke et al., 200938  NA | Overall N: NR  G1: 66.2 (13.1)  G2: 63.8 (13.4) | Overall N: NR  G1: 48.6  G2: 41.9 | **Black:**  Overall N: NR  G1: 65.7  G2: 54.8  **White**:  Overall N: NR  G1: 34.3  G2: 41.9  **Asian**:  Overall N: NR  G1: 0.00  G2: 3.23 | Yes | **Family income based on zip code**:  Overall N: NR  G1: ≤35K: 34.4%; 35-50K: 22.9%; 57-75K: 11.4%; >75K: 31.4%; unknown: 0%  G2: ≤35K: 25.8%; 35-50K: 16.1%; 50-75K: 38.7%; >75K: 16.1%; unknown: 3.23%  **Depression score mean (SD):**  Overall N: NR  G1: 0.47 (0.46)  G2: 0.42 (0.54)  **BL adherence:**  Overall N: NR  G1: 54%  G2: 46% | Column Q: NIH, Pharma company (Alcon), grant from the Paul & Evanina Bell Mackall Foundation Trust, and the Wilmer Institute Research Program. |
| Pearce et al., 200839 Cardiovascular Risk Education and Social Support (CaRESS) Trial | Overall N: Mean (SD) = 62.1 (10.79) G1: Mean (SD) = 60.3 (9.44) G2: Mean (SD) = 62.0 (11.51) G3: Mean (SD) = 63.1 (10.98) | Overall N: 55.3% G1: 48.0% G2: 65.5% | **White** Overall N: 86.9% G1: 88.0% G2: 82.8%  **African-American** Overall N: 13.1%  G1: 12.0% G2: 17.2% | Yes | **Health insurance (%)** Group/private: Overall N: 60.9%  G1: 53.1%  G2: 51.9%  G3: 70.3%  Medicaid/Medicare: Overall N: 32.8%  G1: 32.7%  G2: 42.3%  G3: 27.5%  Other:  Overall N: 1.0%  G1: 0.0%  G2: 3.7%  G3: 0.0%  None:  Overall N: 5.2%  G1: 14.3%  G2: 1.9%  G3: 2.2%  **Employment (%)** Employed:  Overall N: 37.5%  G1: 47.9%  G2: 35.2%  G3: 33.3%  Retired:  Overall N: 47.9%  G1: 37.5%  G2: 46.3%  G3: 54.4% | **Other Theoretical model** = Self-efficacy theories also incorporated |
| Pearce et al., 200839 Cardiovascular Risk Education and Social Support (CaRESS) Trial  (continued) |  |  |  |  | Unemployed/ disabled:  Overall N: 14.6%  G1: 14.6%  G2: 18.5%  G3: 12.3%  **Education (%)** < Some high school: Overall N: 16.6%  G1: 20.0%  G2: 13.8%  G3: 16.5%  High school/GED: Overall N: 41.2%  G1: 44.0%  G2: 39.7%  G3: 40.7%  2-year degree/some college:  Overall N: 22.6%  G1: 16.0%  G2: 25.9%  G3: 24.2%  > 4-year college graduate:  Overall N: 19.6%  G1: 20.0%  G2: 20.7%  G3: 18.7% |  |
| Powell et al., 199540 NA | Overall N: NR G1: Mean (range) = 54 (20-94) G2: 55 (20-97) | Overall N: NR G1: 65% G2: 68% | NR | No | NA | **Funding source - Multiple** = Pharma (Merck & Co.) and corporate (Ciba-Geigy) **Theoretical model - Other** = NS |
| Powers et al., 201168 | Overall N: 67 (8) G1: 68 (9) G2: 65 (8) | Overall N: 2% G1: 2% G2: 2% | **White** Overall N: 51% G1: 50% G2: 51%  **Black** Overall N: 45% G1: 46% G2: 44% | Yes | **Self-reported medication nonadherence**, %: Overall N: 49% G1: 50% G2: 49%  **Self-reported medication adherence** (Morisky scale), %: Overall N: NR G1: 50% G2: 51%  **Diabetes**, %: Overall N:55% G1: 48% G2: 62%  **CHD**, %: Overall N:44% G1: 48% G2: 40%  **Atrial fibrillation**, %: Overall N:9% G1: 9% G2: 9%  **Left ventricular hypertrophy**, %: Overall N:27% G1: 27% G2: 27% | NA |
| Pyne et al., 201141 HIV Translating Initiatives for Depression Into Effective Solutions (HITIDES) | Overall N: 249 G1: 49.8(8.7) G2: 49.8(10.5) | Overall N: 7 G1: N: 3 G2: N: 4 | **African American** Overall N: 155 G1: 63.4% G2: 61.6% | Yes | **Income greater than $20K:**  G1: 60 (50.8%) G2: 52 (42.6%)  **Physical health comorbidity score, mean (SD):**  G1: 3.2 (2.3) G2: 3.8 (2.3) p=.046 | col X: theory of Other |
| Rich et al., 199642  NA | Overall N: 80 (median)  G1: 80.5 (6.7)  G2: 78.4 (6.1)  p: 0.029 | Overall N: 67%  G1: 74%  G2: 59%  p: 0.079 | **Caucasian**  Overall N: 35%  G1: 40%  G2: 29% | Yes | **Education > 8th grade, %:**  Overall: NR  G1: 60%  G2: 51%  **Hypertension, %:**  Overall: NR  G1: 81%  G2: 83%  **Diabetes, %:**  Overall: NR  G1: 25%  G2: 32%  **Prior heart failure, %:**  G1: 68%  G2: 82%  p 0.067 | **Other Theoretical model:**  Not specified  **Heart rate, mean**:\*  G1: 92 (+/- 20)  G2: 83 (+/- 19)  p: 0.004\*  **Hemoglobin (g/L), mean**:  G1: 125 (+/- 18)  G2: 120 (+/- 19)  p: 0.087  **Creatinine (mmol/L), Mean**:  G1: 137 +/- 66  G2: 158 +/- 83  p: 0.083  **Serum Cholesterol (mmol/L), mean:**  G1: 5.3 +/- 1.3G2: 4.8 +/- 1.4  p: 0.052 |
| Rickles et al., 200543  NA | Overall N: 63  G1: 37.8 ± 10.7  G2: 37.5 ± 13.4 | Overall N: G1: 25 (80.6%)  G2: 28 (87.5%) | **White**  Overall N: G1: 27 (87.1)  G2: 31 (96.9)  **Other:**  Overall N:  G1: 4 (12.9)  G3:1 (3.1) | Yes | **Current number of medications other than antidepressants** Overall N:  G1: 0.87 ± 1.41  G2: 0.78 ± 1.16  **No past history of psychiatric medication use, No. (%)**  G1:18 (58.1) G2:27 (84.4)  **Past use of psychiatric medications, No. (%)**  G1:13 (41.9)  G2: 5 (15.6)  P<.05 | **Other Teoretical Model** = health collaboration model |
| Ross et al., 200444 NR | Overall N: NR G1: 57 (NR) G2: 55 (NR) | Overall N: NR G1: 20  G2: 26 | **White, non-Hispanic** Overall N: NR G1: 92 G2: 88 | Yes | **College graduate, %** Overall N: NR G1: 53 G2: 44 p <0.001 comparing participants to decliners (26% in decliners)  **Household income<$45,000/year, %** Overall N: NR G1: 56 G2: 50 p <0.001 comparing participants to decliners (76% in decliners)  **Safety net insurance program, %** Overall N: NR G1: 19 G2: 19  **Morisky BL score**  Overall: 3.4 G1: NR G2: NR  **GAS BL score:** Overall: 82 G1: NR G2: NR | **Other Theoretical model:** NS |
| Rudd et al., 200445  NA | Overall N: NR  G1: 59 (10)  G2: 60 (9) | Overall N: NR  G1: 50  G2: 56 | **White**  Overall N: NR G1: 76  G2: 72  **African American**  Overall N: NR  G1: 11  G2: 8  **Asian American**  Overall N: NR  G1: 4  G2: 4  **Hispanic**  Overall N: NR  G1: 1  G2: 8  **Other ethnicity**  Overall N: NR  G1: 8  G2: 8 | Yes | **Some high school, %**  Overall N: NR  G1: 5  G2: 5  **High school graduate, %**  Overall N: NR  G1: 17  G2: 19  **Some college, %**  Overall N: NR  G1: 24  G2: 23  **College degree, %**  Overall N: NR  G1: 27  G2: 31  **Postdoctoral degree, %**  Overall N: NR  G1: 27  G2: 22  **Dyslipidemia, %** (p<0.05)  Overall N: NR  G1: 16  G2: 30 | **Other Funding**: CorSolution’s, Inc. |
| Rudd et al., 200946  NA | Overall N: 127  G1: Mean 57.6 (13.8)  G2: Mean 59.5 (13.9) p=0.43%  ≥65 years old  G1: 25%  G2: 43%  p: 0.03 | Overall N: 127  G1: 81  G2: 78 | **Caucasian**  Overall N: 127  G1: 91  G2: 94 | Yes | **Annual income <$30K**  Overall N: 127  G1: 20%  G2: 39%  p=0.02 | Other Study Design: RCT with stratified randomization based on education level. |
| Schaffer et al., 200447 NA | Overall N: 44 mean age 37 G1: NR G2: NR G3: NR G4: NR  No statistical differences across groups | Overall N: 29/44 (65.9%)  G1: NR G2: NR G3: NR G4: NR No statistical difference across groups | 17% AA, 72% white, 1% Hispanic, Asian, or Pacific Islander; not reported by study arm; no statistical differences across groups | No | No baseline characteristics reported by study arm; however, across all study arms authors report that there were no statistical differences in years since asthma diagnosis, education, self-reported adherence, pharmacy-reported adherence, or baseline FEV1. |  |
| Schectman et al., 199448 NA | Niacin Overall N: NR G1: 59 (1) G2: 62 (1)  BAS Overall N: NR G1: 61 (2) G2: 59 (2) | Niacin Overall N: NR G1: NR G2: NR  BAS Overall N: NR G1: NR G2: NR | **Caucasian**  Niacin Overall N: NR G1: 86 G2: 90  **BAS** Overall N: NR G1: 86 G2: 82 | Yes | **CHD, Diabetes, HTN, %** Niacin Overall N: NR G1: 39, 2, 56 G2: 42, 4, 63  **BAS** Overall N: NR G1: 35, 24, 62 G2: 37, 13, 52 | **Multiple funding sources:** Gov’t, Pharma (Squibb-Bristol)  **Other Theoretical model:** NS |
| Schneider et al., 200849 NA | Overall N: 85 G1: 71.6 (5.9) G2: 72.3 (5.2) | Overall N: 85 G1: 24.7 G2: 25.9 | Overall N: 85 G1: NR G2: NR | yes | **Renal impairment (SCr>1.2mg/dl)** Overall N: 85 G1: 6.5 G2: 7.9 |  |
| Schnipper et al., 200650 NA | Overall N: 176 G1: 60.7 (17.2) G2: 57.7 (15.9) | Overall N: 176 G1: 67 G2: 65 | Overall N:  G1: NR G2: NR | No | NA | **Other Funding Source**: Pharma, university, Gov’t |
| Simon et al., 200651 NA | Overall N:  G1: 41±15 G2: 45±13 | Overall N:  G1: 71 (69%) G2: 63 (61%) | **White** Overall N:  G1: 92 (89%) G2: 93 (89%) | Yes | **Severity: SCL depression scale** Overall N:  G1: 1.61±.68  G2: 1.57±.71  **Patient Health Questionnaire score** (0 to 27 range; higher scores indicate more severe depression) G1: 16.0±6.2  G2: 15.8±6.1 95% CI,  p: .84 | **Other Funding Source:** funding from gov't and pharma  **Other Theoretical Model**: NS |
| Sledge et al., 200652  NA | Overall N: 96  G1: 53 (range 24-84)  G2: 49 (range 23-80) | Overall N: 96  G1: 26  G2: 41 | Overall N: 96  **Caucasian**  G1: 32  G2: 31  **African American**  G1: 49  G2: 51  **Hispanic**  G1: 13  G2: 12 | Yes | **Medicare/Medicaid**  Overall N: 96  G1: 95%  G2: 92%  **Gross income <$20K**  G1: 89%  G2: 86%  **Congestive heart failure**  G1: 17%  G2: 12%  **Coronary artery disease**  G1: 17%  G2: 18%  **COPD**  G1: 23%  G2: 16%  **Diabetes mellitus**  G1: 28%  G2: 24%  **ESRD/CRI**  G1: 4%  G2: 6%  **Chronic pain**  G1: 11%  G2: 6%  **Asthma**  G1: 19%  G2: 20% | **Other Funding Source:** Aetna health insurance company grant and Esther S. Gross Professorship  **Other Conditions:** multiple conditions, NS |
| Smith et al., 200853  NR | Overall: NR  G1: 64.69 (14.19)  G2: 65.04 (13.38) | Overall: NR  G1: 31.3  G2: 34.0 | NR | Yes | **Medicare, %**  Overall: NR  G1: 46.4  G2: 47.1  **Medicaid, %**  Overall: NR  G1: 1.6  G2: 1.6  **Adherence, Proportion of days covered in month before intervention, %**  G1: 87  G2: 86 | No theoretical model specified |
| Solomon et al., 199854  NA  Gourley et al., 199855  NA | Overall N (HTN); NR  G1: 66.3 (10.0 SD)  G2: 67.3 (11.0 SD)  Overall (COPD): NR  G1: 69.3 (5.9 SD)  G2: 69.3 (9.2 SD) | Overall N (HTN): NR  G1: 1.6%  G2: 7.1%  Overall (COPD): NR  G1: 0  G2: 0 | **Overall N (HTN)**: NR  G1: Caucasian 61.9%  Black 34.9%  Asian 0  Hispanic 0  Missing 3.2%  G2: Caucasian 65.7%  Black 22.9%  Asian 1.4%  Hispanic 0  Missing 10.0%  **Overall N (COPD)**: NR  G1: Caucasian 90.7%  Black 2.3%  Asian 0  Hispanic 7.0%  Missing 0  G2: Caucasian 83.6%  Black 7.3%  Asian 0  Hispanic 9.1%  Missing 0 | Yes | **Income**: **(HTN):** Overall: NR  G1: $18,254 (12,259 SD)  G2: $19,548 (16860 SD)  **Income: (COPD):**  Overall: NR  G1: $20,908 (17,977 SD)  G2: $21,022 (13,029 SD) | **Notes:** Medication adherence improved in hypertension arm; medication adherence did not improve in COPD arm (measures not reported in COPD arm) |
| Stacy et al., 200956 NA | <50 yrs old (%) Overall N: 28.0 G1: 25.3 G2: 30.5  50-64 yrs old (%) Overall N: 62.4 G1: 64.4 G2: 60.2  65 yrs or older (%) Overall N: 9.7 G1: 9.0 G2: 10.3 | Overall N: 62.4 G1: 62.1 G2: 62.7 | Overall N: NR G1: NR G2: NR | Yes | **Mean of 3+ chronic medications dispensed =<90 days prior to index statin (%)** Overall N: 57.8 G1: 53.4 G2: 62.3  **Statin adherence: % started statin, never missed dose** Overall N: 72.9 G1: 71.5 G2: 74.1  **Statin adherence: % started statin, missed 1+ dose** Overall N: 21.9 G1: 22.1 G2: 21.7  **Statin adherence: % not yet started statin** Overall N: 5.2 G1: 6.3 G2: 4.2 | Funding Source: NR |
| Taylor et al., 200357  NA | Overall N: 69  G1: 64.4 (13.7)  G2: 66.7 (12.3) | Overall N: 69  G1: 63.6  G2: 72.2 | **White**  Overall N: 69%  G1: 60.6  G2: 61.1 | Yes | **Mean % (SD) adherent at BL (compliance scores ≥80%):**  Overall N: 69  G1: 84.9 (6.7)  G2: 88.9 (5.8) | **Other Conditions:** multiple conditions  **Other Theoretical Model:** Principles of Pharmaceutical Care |
| Vivian et al., 200258 NA | Overall N: NR G1: 64 (10.9) G2: 65.5 (7.8) | Overall N: NR G1: 0 G2: 0 | **African American** Overall N: 77 G1: 84.6 G2: 70.4  **Caucasian** Overall N: 77 G1: 11.5 G2: 25.9 | Yes | **Diabetes, %** Overall N: NR G1: 42 G2: 59 | **Other Theoretical model:** not specified |
| Waalen et al., 200959 NA | Overall N: 237 G1: 71.3 (7.3) G2: 70.5 (12.6) | Overall N: 237 G1: 100% G2: 100% | **White** Overall N: 237 G1: 91.2 G2: 98.2  **Hispanic** Overall N: 237 G1: 2.4 G2: 0.9  **Asian** Overall N: 237 G1: 5.6  G2: 0.9  **Black**  G1: 0.8  G2: 0 | No | NA | NA. |
| Wakefield et al., 201160  NA | Overall N: 68 (10) G1: 67.8 (10) G2: 68.4 (9.5) G3: 69.9 (9.9) | Overall N: 2% G1: 1% G2: 1% G3: 4% | **American Indian/Alaska Native** Overall N: NR G1: 0% G2: <1% G3: 2%  **Black/African American** Overall N: NR G1: 3% G2: 2% G3:<1%  **Hispanic** Overall N:NR  G1: 0% G2: <1% G3: <1%  **White** Overall N: 96% G1: 97% G2: 96% G3 95% | No | NA | NA |
| Weinberger et al., 200261 NA | COPD: mean (SD) Overall N: 453 G1: 62.2 (11.0) G2: 62.9 (10.3) G3:62.2 (11.9)  Asthma: Overall N: 660 G1: 44.7 (14.2) G2: 46.6 (15.1) G3:44.6 (15.5) | COPD:  number (%) Overall N: 453 G1:118 (63.8) G2: 86 (66.2)  G3:93 (67.4)  Asthma: Overall N: 660 G1: 210 (80.2) G2: 190 (81.6)  G3:139 (84.2) | **White**, % COPD:  number (%) Overall N: 453 G1:149 (80.5) G2: 116 (89.2) G3:127 (92.0)   Asthma: Overall N: 660 G1: 197 (75.2) G2: 189 (81.1) G3:145 (87.9) | Yes | **Medication compliance, No (%) not compliant**  COPD Overall N: 453 G1: 64 (34.8)  G2: 46 (35.4)  G3: 54 (39.0)  Asthma: Overall N: 660 G1: 91 (34.7)  G2: 77 (33.1)  G3: 61 (37.2) | **Other Randomization**: randomization was stratified within cluster of 3 proximal drugstores    **Other Theoretical Model**: not reported |
| Weinberger et al., 200261 NA  (continued) |  |  | within both conditions, race differed by group (p<0.05) |  | **Med compliance - 4 item measure, mean SD** COPD Overall N: 453 G1: 1.3 (1.2) G2: 1.1 (1.0)  G3: 1.0 (1.1)  Asthma Overall N: 660 G1: 1.4 (1.1)  G2: 1.2 (1.1)  G3: 1.4 (1.2)  **Peak expiratory flow rates (PEFR), mean SD, % predicted** COPD: Overall N: 453 G1: 52.1 (21.1)  G2:46.4 (19.8) G3:48.1 (18.4)  p<.05 Asthma: Overall N: 660 G1:70.0 (18.0) G2:69.5 (18.5)  G3:70.8 (19.2) p>=.05 | **Note**: baseline characteristics presented stratified by disease (COPD vs.asthma) |
| Weymiller et al., 200762  Statin Choice Randomized Trial  Jones et al., 200963  Statin Choice Randomized Trial | Overall N: Mean (SD) = NR G1: Mean (SD) = 64 (12)  G2: Mean (SD) = 66 (8)  Overall N: Mean (SD) = NR  G1: Mean (SD) = 65.4 (11.1)  G2: Mean (SD) = 63.4 (12.7)  G3: Mean (SD) = 67.4 (8.0)  G4: Mean (SD) = 65.8 (8.1) | Overall N: NR  G1: 31%  G2: 57%  Overall N: NR  G1: 26.9%  G2: 34.6%  G3: 56.5%  G4: 56.5% | NR | Yes | **Diagnosis of CAD**  G1: N (%) = 26 (50%)  G2: N (%) = 20 (43%)  **United Kingdom Prospective Diabetes Study (UKPDS) estimated 10-year**  **Cardiovascular risk <15%**  G1: N (%) = 6 (12%)  G2: N (%) = 15 (33%)  **15-30%**  G1: N (%) = 16 (31%)  G2: N (%) = 7 (15%)  **>30%**  G1: N (%) = 30 (58%)  G2: N (%) = 24 (52%)  **Diagnosis of CAD**  G1: N (%) = 15 (57.7%) | **Other Randomization** = Providers were randomized to treatment or control, and patients were randomized to receive the intervention or control materials either from their clinician during the visit or from a researcher before the visit  **Funding source - Multiple** = Foundation/non-profit and Mayo Clinic-affiliated patient education center  **Other**  **Theoretical model** - Other = NS  **BL characteristics - Other** =High school education completed  Overall N: NR  G1: N (%) = 51 (98%)  G2: N (%) = 39 (87%)  High school education  Overall N: NR  G1: N (%) = 25 (96.2%)  G2: N (%) = 26 (100.0%) |
| Weymiller et al., 200762  Statin Choice Randomized Trial  Jones et al., 200963  Statin Choice Randomized Trial  (continued) |  |  |  |  | **UKPDS estimated 10-year cardiovascular risk<15%**  G1: N (%) = 4 (15.4%)  G2: N (%) = 2 (7.7%)  G3: N (%) = 8 (34.8%)  G4: N (%) = 7 (30.4%)  **15-30%**  G1: N (%) = 7 (26.9%)  G2: N (%) = 9 (34.6%)  G3: N (%) = 5 (21.7%)  G4: N (%) = 2 (8.7%)  **>30%**  G1: N (%) = 15 (57.7%)  G2: N (%) = 15 (57.7%)  G3: N (%) = 10 (43.5%)  G4: N (%) = 14 (60.9%) | G3: N (%) = 22 (95.7%)  G4: N (%) = 17 (77.3%) |
| Williams et al., 201064 NA | Overall N: 2698 G1: 26.8 +/- 17.4 G2: 28.8 +/- 17.4 | Overall N: 1490 G1: 737 (55.2%)  G2: 753 (55.3%) | **African American** Overall N: 1039 G1: 511 (38.3)  G2: 528 (38.7)  **White** Overall N: 1475 G1: 726 (54.4) G2: 749 (55.0)  **Other** Overall N: 184 G1: 98 (7.3)  G2: 86 (6.3) | No | NA | **Other Theoretical model**: none **Other randomization**: clustered randomization was stratified by type of clinical practice: pediatrics vs. family medicine and internal medicine  **Notes:** Usual care group was given extensive educational materials in a variety of formats. G1 providers given opportunity to access adherence data in addition. |
| Wilson et al., 201065  Better Outcomes of Asthma Treatment (BOAT); note that there is online supplemental material for methods and timeline | Overall N:612  G1: 45.7 +/- 13.3  G2: 46.9 +/- 12.1  G3: 45.1 +/- 12.4 | Overall N: G1: 115 (56.4)  G2: 114 (55.9)  G3: 117 (57.4) | **Caucasian**  G1: 128 (62.8)  G2: 124 (60.8)  G3: 127 (62.3) AA  G1: 32 (15.7)  G2: 34 (16.7)  G3: 30 (14.7)  **Asian**  G1: 20 (9.8)  G2: 18 (8.8)  G3: 22 (10.8) Hispanic  G1: 9 (4.4)  G2: 9 (4.4)  G3: 8 (3.9)  **Pacific Islander**  G1: 15 (7.4)  G2: 16 (7.8)  G3: 17 (8.3)  **American Indian**  G1: 0 (0.0)  G2: 3 (1.5)  G3: 0 (0.0) | Yes | **Severity Level of Asthma control:**  Very poorly controlled  G1: 79 (38.7)  G2: 82 (40.2)  G3: 85 (42.1)  Poorly controlled:  G1: 96 (47.1)  G2: 87 (42.7)  G3: 83 (41.1)  Moderately well controlled:  G1: 17 (8.3)  G2: 24 (11.8)  G3: 29 (14.4)  Well controlled:  G1: 12 (5.9)  G2: 11 (5.4)  G3: 5 (2.5)  **Hospitalized for asthma in past 2 years**  G1:71 (34.8)  G2: 69 (33.8)  G3: 76 (37.3)  **Income >/=40K/yr**  G1: 133 (66.8)  G2: 139 (70.9)  G3: 134 (69.1) | NA |
| Wolever et al., 201066  NA | Overall N: 53 (7.93)  G1: 53.1 (8.29)  G2: 52.8 (7.64) | Overall N: 77%  G1: 73%  G2: 81% | **White**  Overall N: 39%  G1: 33%  G2: 46%  **Black**  Overall N: 57%  G1: 63%  G2: 50%  **Other**  Overall N: 4%  G1: 3%  G2: 4% | Yes | **Household income < $50,000**  Overall N: 55%  G1: 57%  G2: 54%  **Household income > $50,000**  Overall N: 45%  G1: 43%  G2: 46% | **Theoretical model - other** = Integrative health coaching |
| Zhang et al., 201067  NA | **Hyperlipidemia** (N = 9185):  G1 (Age %): 65-74 years, 40.2%; 75-84 years, 53.6%; >85 years, 6.2%  G2 (Age %): 65-74 years, 52.4%; 75-84 years, 41.1%; >85 years, 6.5%  G3 (Age %): 65-74 years, 54.7%; 75-84 years, 40.3%; >85 years, 5%  G4 (Age %): 65-74 years, 62%; 75-84 years, 34.3%; >85 years, 3.7% | **Hyperlipidemia**: G1: 68.4  G2: 65.4  G3: 61.5  G4: 50.9  **Diabetes**  G1: 60.3  G2: 58.2  G3: 56.7  G4: 47.6  **Hypertension**  G1: 69.3  G2: 66.4  G3: 64.7  G4: 53.8  G4 differs from G1, G2, and G3 at p < 0.05 | **Hyperlipidemia:**  **Proportion of white beneficiaries**  G1: 92.3  G2: 96  G3: 92  G4: 92.2  G2 vs. G4, p < 0.05  **Diabetes:**  **Proportion of white beneficiaries**  G1: 92.8  G2: 96.2  G3: 92.1  G4: 91.5  G2 vs. G4, p < 0.05  **Hypertension:**  **Proportion of white beneficiaries**  G1: 91.6  G2: 96.0  G3: 91.6  G4: 91.7  G2 vs. G4, p < 0.05 | Yes | **Hyperlipidemia**:  Median Income ($), mean (SE) Among 65-74 year olds  G1: 26,440 (261)  G2: 25,865 (153)  G3: 28,782 (92)  G4: 28,948 (118)  Among >75 year olds  G1: 19,798 (200)  G2: 19,124 (123)  G3: 20,796 (63)  G4: 20,992 (79)  Proportion living in Urban areas  G1: 72.1  G2: 60.5  G3: 80  G4: 80.2  G1 and G2 differ from G4 at p < 0.05 | **Other level of randomization** = NA  **Multiple funders** = government, nonprofit, and academic  **Other theoretical model** = NS |
| Zhang et al., 201067  NA  (continued) | **Diabetes** (N = 4018)  G1 (Age %): 65-74 years, 41.3%; 75-84 years, 49.8%; >85 years, 8.9%  G2 (Age %): 65-74 years, 50%; 75-84 years, 42.8%; >85 years, 7.2%  G3 (Age %): 65-74 years, 54%; 75-84 years, 39.7%; >85 years, 6.3%  G4 (Age %): 65-74 years, 60.7%; 75-84 years, 34.9%; >85 years, 4.5%  **Hypertension** (N = 14,735)  G1 (Age %): 65-74 years, 37.3%; 75-84 years, 48.6%; >85 years, 14.1%  G2 (Age %): 65-74 years, 44.7%; 75-84 years, 44.6%; >85 years, 10.8%  G3 (Age %): 65-74 years, 48.1%; 75-84 years, 42.5%; >85 years, 9.4% |  |  |  | **Diabetes**  Median Income ($). Mean (SE) Among 65-74 year olds  G1: 26,740 (361)  G2: 25,713 (207)  G3: 27,854 (130)  G4: 28,611 (178)  Among >75 year olds  G1: 19,968 (260)  G2: 19,024 (167)  G3: 20,290 (92)  G4: 20,642 (113)  Proportion living in Urban areas  G1: 74.1  G2: 58.5  G3: 77.5  G4: 77.6  G2 vs. G4, p < .05  **Hypertension** Median Income ($), mean (SE) Among 65-74 year olds  G1: 26,940 (182)  G2: 25,784 (107)  G3: 28,427 (71)  G4: 28,688 (100)  Among >75 year olds  G1: 19,868 (128)  G2: 19,168 (89)  G3: 20,563 (47)  G4: 20,875 (67) |  |
| Zhang et al., 201067  NA  (continued) | G4 (Age %): 65-74 years, 55.9%; 75-84 years, 37.9%; >85 years, 6.2%  G4 differs from G1, G2, and G3 at p < 0.05 |  |  |  | Proportion living in Urban areas  G1: 75.4  G2: 57.9  G3: 79.7  G4: 80.3  G2 vs. G4, p < 0.05 |  |